Cancer Genetics Inc., an emerging leader in DNA-based cancer diagnostics, has  announced the addition of Venkatadri Bobba to its India’s board of directors.

Bobba has over  36 years of corporate leadership experience in the pharmaceutical and life sciences industries.  He is  currently a general partner with Ventureast and  held executive leadership positions at a number of life sciences companies in the US, EU, and Asia. He  is an active board member of three US-based companies: Diabetomics Inc., Melior Pharma, and Sparsha Inc. Besides he is  on the board of several Indian-based companies: Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he is on  advisory board of  SOHO Group, the largest pharmaceutical company in Indonesia and  Cumberland Pharmaceuticals, Inc.

“Bobba has a tremendous track record of leadership in the life sciences. His experiences will bring significant value to CG India’s board of directors,” said Panna Sharma, CEO and president of Cancer Genetics, Inc.

“It is an exciting time to be part of such a high-growth market like India. I look forward to the growth and much needed innovation that CG India will bring to Indian cancer patients and hospitals at an affordable price,” said Bobba.